Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial.

Life Metab · 2025 · PMC13122358 · PMID 42058132

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significanceP = 0.06so close (0.05 < p ≤ 0.1)

Borderline significance was observed for the change in HbA1c in participants receiving tirzepatide versus placebo in a three-group analysis ( P = 0.06).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.